On March 26, 2026, Upstream Bio, Inc. (Nasdaq: UPB) announced its financial results for the fourth quarter and full year ended December 31, 2025, alongside a strategic update on its lead product, verekitug. The company reported a strong cash position of $341.5 million, which is expected to fund operations through 2027. Notably, Upstream Bio highlighted the positive top-line results from its Phase 2 VALIANT trial of verekitug in patients with severe asthma, demonstrating significant improvements in asthma exacerbations and lung function. The trial met its primary endpoint, showing a 56% reduction in the annualized asthma exacerbation rate (AAER) when dosed at 100 mg every 12 weeks. The company plans to initiate Phase 3 trials in both severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027, focusing on a high-dose quarterly regimen designed to maximize efficacy across broad patient populations. This strategic direction is supported by comprehensive analyses from the Phase 2 trials, which indicate that verekitug could deliver best-in-class efficacy with a convenient dosing schedule. Upstream Bio's leadership expressed confidence in the potential of verekitug to become a leading treatment option in the market, emphasizing the importance of efficacy and safety in their development strategy. The company is also actively enrolling participants in its Phase 2 VENTURE trial for chronic obstructive pulmonary disease (COPD), further expanding its clinical portfolio. Overall, the announcements reflect a positive outlook for Upstream Bio as it advances its clinical programs and prepares for future regulatory interactions.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.